Receptos to Hold Fourth Quarter and Year End 2014 Financial Results Conference Call
February 26, 2015 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will review...
Receptos Announces Oral Podium Presentation at Annual Meeting of European Crohn's and Colitis Organization (ECCO)
February 18, 2015 08:00 ET
|
Receptos, Inc.
- Detailed Results of Positive Phase 2 Trial of RPC1063 in Ulcerative Colitis to be Presented on February 21, 2015 -
- Company to Host Investor Call and Webcast on February 23, 2015 -
SAN DIEGO,...
Receptos to Present at Leerink Global Healthcare Conference
February 09, 2015 08:00 ET
|
Receptos, Inc.
SAN DIEGO, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
December 22, 2014 08:00 ET
|
Receptos, Inc.
– Following Positive Phase 2 Results, Receptos Now Enrolling Two Phase 3 Trials in Relapsing Multiple Sclerosis –
– Receptos Well...
Receptos Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock
November 24, 2014 09:48 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Pricing of Underwritten Public Offering of Common Stock
November 18, 2014 20:10 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Announces Proposed Underwritten Public Offering of Common Stock
November 17, 2014 16:01 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos to Present at Credit Suisse Healthcare Conference
November 06, 2014 16:01 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Provides Development Updates and Reports Third Quarter 2014 Financial Results
November 04, 2014 07:00 ET
|
Receptos, Inc.
- Recent positive Phase 2 induction results for TOUCHSTONE trial of RPC1063 in ulcerative colitis (UC) support initiation of broad program in inflammatory bowel disease -
- Enrollment in first...
Receptos to Present at Nomura BioPharma Conference
November 03, 2014 16:01 ET
|
Receptos, Inc.
SAN DIEGO, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...